search icon
catx-img

Perspective Therapeutics Inc., Common Stock

CATX

ASQ

$2.7

+$0.12

(4.65%)

1D
Industry: Health Care Equipment & Supplies Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$186.31M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
605.77K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.13
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.6 L
$16.55 H
$2.7

About Perspective Therapeutics Inc., Common Stock

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington. more

Industry: Health Care Equipment & SuppliesSector: Health Care

Returns

Time FrameCATXSectorS&P500
1-Week Return7.57%0.71%0.79%
1-Month Return12.03%-5.6%6.04%
3-Month Return-2.88%-11.72%-1.11%
6-Month Return-37.93%-10.81%-2.39%
1-Year Return-80%-7.12%11.69%
3-Year Return-3.57%-0.57%42.29%
5-Year Return-62.5%27.64%93.12%
10-Year Return-85%75.45%179.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue10.05M10.79M7.10M1.43M-[{"date":"2020-12-31","value":93.13,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":65.81,"profit":true},{"date":"2023-12-31","value":13.28,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue4.93M6.18M5.47M--[{"date":"2020-12-31","value":79.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":88.53,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit5.12M4.62M1.63M1.43M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":90.14,"profit":true},{"date":"2022-12-31","value":31.91,"profit":true},{"date":"2023-12-31","value":28,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin50.94%42.76%23.00%100.00%-[{"date":"2020-12-31","value":50.94,"profit":true},{"date":"2021-12-31","value":42.76,"profit":true},{"date":"2022-12-31","value":23,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses8.56M18.19M17.43M42.38M92.34M[{"date":"2020-12-31","value":9.27,"profit":true},{"date":"2021-12-31","value":19.69,"profit":true},{"date":"2022-12-31","value":18.87,"profit":true},{"date":"2023-12-31","value":45.89,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(3.44M)(7.39M)(15.18M)(40.94M)10.46M[{"date":"2020-12-31","value":-32.86,"profit":false},{"date":"2021-12-31","value":-70.67,"profit":false},{"date":"2022-12-31","value":-145.16,"profit":false},{"date":"2023-12-31","value":-391.44,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense109.00K--1.69M(81.37M)[{"date":"2020-12-31","value":6.47,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-4828.96,"profit":false}]
Pre-Tax Income(3.39M)(7.27M)(14.67M)(40.11M)(81.38M)[{"date":"2020-12-31","value":-338700000,"profit":false},{"date":"2021-12-31","value":-727200000,"profit":false},{"date":"2022-12-31","value":-1467000000,"profit":false},{"date":"2023-12-31","value":-4010600000,"profit":false},{"date":"2024-12-31","value":-8137600000,"profit":false}]
Income Taxes(199.00K)-(119.00K)(2.65M)(2.10M)[{"date":"2020-12-31","value":-19900000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-11900000,"profit":false},{"date":"2023-12-31","value":-265100000,"profit":false},{"date":"2024-12-31","value":-209700000,"profit":false}]
Income After Taxes(3.19M)--(37.45M)(79.28M)[{"date":"2020-12-31","value":-318800000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3745500000,"profit":false},{"date":"2024-12-31","value":-7927900000,"profit":false}]
Income From Continuous Operations(3.39M)(7.27M)-(37.45M)(78.33M)[{"date":"2020-12-31","value":-338700000,"profit":false},{"date":"2021-12-31","value":-727200000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3745500000,"profit":false},{"date":"2024-12-31","value":-7833000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(3.19M)(7.27M)(14.67M)(46.51M)(79.28M)[{"date":"2020-12-31","value":-318800000,"profit":false},{"date":"2021-12-31","value":-727200000,"profit":false},{"date":"2022-12-31","value":-1467000000,"profit":false},{"date":"2023-12-31","value":-4650800000,"profit":false},{"date":"2024-12-31","value":-7927900000,"profit":false}]
EPS (Diluted)(0.05)(0.05)(0.07)(0.18)(0.83)[{"date":"2020-12-31","value":-5,"profit":false},{"date":"2021-12-31","value":-5,"profit":false},{"date":"2022-12-31","value":-7,"profit":false},{"date":"2023-12-31","value":-18,"profit":false},{"date":"2024-12-31","value":-83.33,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CATX
Current Ratio 17.02

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CATX
ROA (LTM) -15.56%
ROE (LTM) -32.92%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CATX
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CATX
Trailing PE NM
Forward PE NM
P/S (TTM) 130.19
P/B 0.67
Price/FCF NM
EV/R 68.73
EV/Ebitda NM

FAQs

What is Perspective Therapeutics Inc. share price today?

Perspective Therapeutics Inc. (CATX) share price today is $2.7

Can Indians buy Perspective Therapeutics Inc. shares?

Yes, Indians can buy shares of Perspective Therapeutics Inc. (CATX) on Vested. To buy Perspective Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CATX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Perspective Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Perspective Therapeutics Inc. (CATX) via the Vested app. You can start investing in Perspective Therapeutics Inc. (CATX) with a minimum investment of $1.

How to invest in Perspective Therapeutics Inc. shares from India?

You can invest in shares of Perspective Therapeutics Inc. (CATX) via Vested in three simple steps:

  • Click on Sign Up or Invest in CATX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Perspective Therapeutics Inc. shares
What is Perspective Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of Perspective Therapeutics Inc. (CATX) is $16.55. The 52-week low price of Perspective Therapeutics Inc. (CATX) is $1.6.

What is Perspective Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Perspective Therapeutics Inc. (CATX) is 0.67

What is the Market Cap of Perspective Therapeutics Inc.?

The market capitalization of Perspective Therapeutics Inc. (CATX) is $186.31M

What is Perspective Therapeutics Inc.’s stock symbol?

The stock symbol (or ticker) of Perspective Therapeutics Inc. is CATX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top